Pembrolizumab Monotherapy Following Tri-modality Treatment for Selected Patients With Muscle-invasive Bladder Cancer

NCT05072600 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

54

Enrollment

OTHER

Sponsor class

Conditions

Bladder Cancer
Bladder Neoplasms
Bladder Tumors
Urinary Bladder Cancer
Neoplasms, Bladder

Interventions

DRUG: Pembrolizumab

Sponsor

Peking University First Hospital